Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Phase of Trial: Phase I/II
Latest Information Update: 30 Apr 2017
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Translational Biosciences
- 26 Aug 2016 Status changed from active, no longer recruiting to completed.
- 04 Feb 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.
- 18 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.